Biopharma companies, BARDA call for more clarity on FDA’s new platform tech proposal

Fol­low­ing the FDA’s May re­lease of long-await­ed draft guid­ance ex­plain­ing how com­pa­nies can win des­ig­na­tions for cer­tain cell and gene ther­a­py “plat­form” tech­nolo­gies, com­pa­nies like …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.